The clusterin paradigm in prostate and breast carcinogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Clusterin (CLU) exhibits diverse biological functions and protein forms, leading to complex roles in tumorigenesis.
• Previous research on CLU's involvement in cancer has yielded contradictory findings.
• Understanding CLU's function is challenging due to its multiple isoforms and the dynamic nature of tumors.

Purpose of the Study:

• To review recent discoveries on the role of CLU in prostate and breast cancer.
• To elucidate the dual function of CLU in early and late-stage carcinogenesis.
• To investigate CLU's impact on tumor progression and treatment resistance.

Main Methods:

• Literature review of recent studies on CLU in cancer.
• Analysis of CLU expression patterns in different cancer stages.
• Examination of CLU's association with therapeutic interventions.

Main Results:

• CLU functions as a tumor suppressor in early carcinogenesis.
• Late-stage cancers may overexpress CLU, particularly after chemotherapy or hormone ablation.
• High CLU expression can confer resistance to anti-cancer drugs and enhance tumor cell survival.

Conclusions:

• CLU's role in cancer is context-dependent, shifting from suppression to promotion.
• Secreted and cytoplasmic CLU isoforms may act as pro-survival factors in advanced cancers.
• Further research is needed to fully understand CLU's complex mechanisms in tumorigenesis and treatment response.